Novo Nordisk Price Target Rises to $80 as Oral Wegovy Surpasses 3 Million Prescriptions
Novo Nordisk received an upgraded price target of $80, while market analysts assigned the stock a Modest Buy rating….
-
-
Oral Semaglutide & Levothyroxine: Key Facts
Oral semaglutide (often prescribed as Rybelsus) has made a big difference in how we manage weight loss and diabetes….
-
Smart Snacking Strategies for Patients on GLP-1 Receptor Agonist Therapy
GLP-1 receptor agonists have changed the way doctors treat obesity and type 2 diabetes. Drugs like semaglutide and tirzepatide…
-
MindRank Secures Fifty-Two Million Series B for Oral GLP-1 Candidate
MindRank, a drug discovery company that uses artificial intelligence, recently completed a fifty-two million dollar Series B financing round….
-
Clinical Trial Evaluates Oral Orforglipron Against Semaglutide
A new once-daily tablet, orforglipron, outperformed oral semaglutide in a phase 3 clinical trial. Researchers evaluated this new receptor…
-
Clinical Trial Confirms Significant Weight Loss for Investigational Oral GLP-1 Therapy
An investigational once-daily pill designed to activate the GLP-1 receptor produced measurable weight loss in a mid-stage clinical trial….
-
Corxel-Vincentage’s Oral GLP-1 Achieves Positive Phase II Obesity Trial Results
Obesity medicine is changing fast as companies work on making weight-loss pills instead of just shots. Corxel Pharmaceuticals and…
-
Oral GLP-1s at the Bench: Moving from Pens to Pills
The GLP-1 receptor agonist class started when national regulators approved exenatide for diabetes management. Researchers first developed these molecules…
-
Oral Semaglutide Gains UK Approval, Raising Hopes for Greater Access to GLP-1 Therapy
People dealing with weight management just got a brand-new option. For the first time, health regulators have approved a…
-
Oral GLP-1 Drugs Advance as Pharmaceutical Companies Race Toward Pill-Based Weight Loss Treatments
Multiple pharmaceutical companies are developing oral versions of GLP-1 receptor agonists. This class of drugs has changed the treatment…
